Logo image of ALVO

ALVOTECH SA (ALVO) Stock Fundamental Analysis

USA - NASDAQ:ALVO - LU2458332611 - Common Stock

8.735 USD
+0.04 (+0.4%)
Last: 9/24/2025, 9:31:37 AM
Fundamental Rating

4

Taking everything into account, ALVO scores 4 out of 10 in our fundamental rating. ALVO was compared to 538 industry peers in the Biotechnology industry. There are concerns on the financial health of ALVO while its profitability can be described as average. ALVO is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

ALVO had negative earnings in the past year.
ALVO had a negative operating cash flow in the past year.
In the past 5 years ALVO always reported negative net income.
In the past 5 years ALVO always reported negative operating cash flow.
ALVO Yearly Net Income VS EBIT VS OCF VS FCFALVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -200M -400M

1.2 Ratios

ALVO has a better Return On Assets (4.55%) than 91.45% of its industry peers.
ALVO's Return On Invested Capital of 3.89% is amongst the best of the industry. ALVO outperforms 92.19% of its industry peers.
Industry RankSector Rank
ROA 4.55%
ROE N/A
ROIC 3.89%
ROA(3y)-46.35%
ROA(5y)-38.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALVO Yearly ROA, ROE, ROICALVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

The Profit Margin of ALVO (11.26%) is better than 92.75% of its industry peers.
ALVO has a better Operating Margin (9.75%) than 92.19% of its industry peers.
ALVO's Gross Margin of 53.88% is fine compared to the rest of the industry. ALVO outperforms 76.21% of its industry peers.
Industry RankSector Rank
OM 9.75%
PM (TTM) 11.26%
GM 53.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALVO Yearly Profit, Operating, Gross MarginsALVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

2

2. Health

2.1 Basic Checks

ALVO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for ALVO has been increased compared to 1 year ago.
Compared to 1 year ago, ALVO has an improved debt to assets ratio.
ALVO Yearly Shares OutstandingALVO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100M 200M 300M
ALVO Yearly Total Debt VS Total AssetsALVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ALVO has an Altman-Z score of -0.52. This is a bad value and indicates that ALVO is not financially healthy and even has some risk of bankruptcy.
ALVO has a Altman-Z score (-0.52) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.52
ROIC/WACC0.57
WACC6.78%
ALVO Yearly LT Debt VS Equity VS FCFALVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

ALVO has a Current Ratio of 1.82. This is a normal value and indicates that ALVO is financially healthy and should not expect problems in meeting its short term obligations.
ALVO has a worse Current ratio (1.82) than 78.07% of its industry peers.
A Quick Ratio of 1.27 indicates that ALVO should not have too much problems paying its short term obligations.
The Quick ratio of ALVO (1.27) is worse than 83.27% of its industry peers.
Industry RankSector Rank
Current Ratio 1.82
Quick Ratio 1.27
ALVO Yearly Current Assets VS Current LiabilitesALVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

ALVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 64.39%, which is quite impressive.
Looking at the last year, ALVO shows a very strong growth in Revenue. The Revenue has grown by 426.84%.
ALVO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 42.86% yearly.
EPS 1Y (TTM)64.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)426.84%
Revenue growth 3Y131.44%
Revenue growth 5Y42.86%
Sales Q2Q%0%

3.2 Future

Based on estimates for the next years, ALVO will show a very strong growth in Earnings Per Share. The EPS will grow by 46.57% on average per year.
ALVO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 44.38% yearly.
EPS Next Y96.48%
EPS Next 2Y60.27%
EPS Next 3Y46.57%
EPS Next 5YN/A
Revenue Next Year44.99%
Revenue Next 2Y43.62%
Revenue Next 3Y44.38%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ALVO Yearly Revenue VS EstimatesALVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 500M 1B 1.5B
ALVO Yearly EPS VS EstimatesALVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALVO. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 17.66, the valuation of ALVO can be described as rather expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ALVO indicates a rather cheap valuation: ALVO is cheaper than 93.68% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.87, ALVO is valued a bit cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 17.66
ALVO Price Earnings VS Forward Price EarningsALVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ALVO is valued cheaply inside the industry as 90.89% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 43.23
ALVO Per share dataALVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ALVO's earnings are expected to grow with 46.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y60.27%
EPS Next 3Y46.57%

More info and screens

0

5. Dividend

5.1 Amount

ALVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALVOTECH SA

NASDAQ:ALVO (9/24/2025, 9:31:37 AM)

8.735

+0.04 (+0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-12 2025-11-12/amc
Inst Owners6%
Inst Owner ChangeN/A
Ins Owners0.46%
Ins Owner ChangeN/A
Market Cap2.72B
Analysts78
Price Target17.85 (104.35%)
Short Float %1.25%
Short Ratio3.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)484.73%
Min EPS beat(2)411.94%
Max EPS beat(2)557.52%
EPS beat(4)4
Avg EPS beat(4)268.35%
Min EPS beat(4)38.96%
Max EPS beat(4)557.52%
EPS beat(8)5
Avg EPS beat(8)624.3%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)39.02%
Min Revenue beat(2)37.03%
Max Revenue beat(2)41.02%
Revenue beat(4)4
Avg Revenue beat(4)30.46%
Min Revenue beat(4)13.45%
Max Revenue beat(4)41.02%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.47%
Revenue NY rev (3m)1.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 17.66
P/S 4.84
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 43.23
EPS(TTM)-0.87
EYN/A
EPS(NY)0.49
Fwd EY5.66%
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS1.81
BVpS-0.56
TBVpS-0.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.55%
ROE N/A
ROCE 4.93%
ROIC 3.89%
ROICexc 4.51%
ROICexgc 4.85%
OM 9.75%
PM (TTM) 11.26%
GM 53.88%
FCFM N/A
ROA(3y)-46.35%
ROA(5y)-38.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 13.65
Cap/Depr 288.56%
Cap/Sales 17.29%
Interest Coverage 2.5
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.82
Quick Ratio 1.27
Altman-Z -0.52
F-Score5
WACC6.78%
ROIC/WACC0.57
Cap/Depr(3y)204.72%
Cap/Depr(5y)182.09%
Cap/Sales(3y)39.66%
Cap/Sales(5y)47.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y96.48%
EPS Next 2Y60.27%
EPS Next 3Y46.57%
EPS Next 5YN/A
Revenue 1Y (TTM)426.84%
Revenue growth 3Y131.44%
Revenue growth 5Y42.86%
Sales Q2Q%0%
Revenue Next Year44.99%
Revenue Next 2Y43.62%
Revenue Next 3Y44.38%
Revenue Next 5YN/A
EBIT growth 1Y144.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year191.3%
EBIT Next 3Y86.48%
EBIT Next 5YN/A
FCF growth 1Y59.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.78%
OCF growth 3YN/A
OCF growth 5YN/A